0.64%

Dow Jones

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

CNTA Centessa Pharmaceuticals PLC

9.86

0.29 (3.03%)

Jul 12 2024 - Closed

Delayed by 15 minutes

Centessa Gets FDA Orphan Designation for SerpinPC in Hemophilia B

By Colin Kellaher

Centessa Pharmaceuticals PLC on Wednesday said the U.S. Food and Drug Administration granted orphan-drug designation to its lead candidate SerpinPC for the treatment of the hereditary bleeding disorder hemophilia B.

The U.K.-based clinical-stage pharmaceutical company said it plans to begin registrational studies of SerpinPC in the fourth quarter.

The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. and provides for an extended marketing exclusivity period against competition.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

September 14, 2022 09:29 ET (13:29 GMT)

Centessa Pharmaceuticals (NASDAQ:CNTA)
Historical Stock Chart
From Jun 2024 to Jul 2024